Skip to main content
main-content

08.05.2020 | Original Research

Comparison of ICRU 38 rectal reference point dose estimates with measured dose in vivo in cobalt-60 HDR brachytherapy for cervical cancer

Zeitschrift:
Journal of Radiation Oncology
Autoren:
Cesar Vincent L. Villafuerte III, Edilberto Joaquin V. Fragante Jr, Marivic Bacaling Candado
Wichtige Hinweise

Presentation

• Poster Presentation, 3rd FARO Meeting (Federation of Asian Organizations for Radiation Oncology) September 6–8, 2018, Bali, Indonesia.
• First Place, Research Paper Category, Philippine Radiation Oncology Society Annual Resident’s Research Forum 19 August 2017, Hotel Ariana, La Union, Philippines.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Objective

The objective of this study was to compare the ICRU 38 calculated rectal dose with in vivo dosimetry measured doses in cobalt-60 HDR brachytherapy for cervical cancer.

Methods

A total of 48 brachytherapy insertions done on 15 patients treated from January to March 2017 at our institution were included in this prospective cross-sectional study.

Results

The results demonstrated no significant difference between the computed ICRU rectal point dose and in vivo maximum measured rectal dose ((r) 0.6208, p < 0.0001 [S]; t test p = 0.1578 [NS] 95% CI − 0.78 to 0.46), but a significant difference between ICRU rectal point and in vivo mean measured rectal dose ((r) 0.6033, p < 0.0001 [S]; t test p < 0.0001 [S] 95% CI − 0.81 to 0.35). These findings were seen even when sub-analyzed for the two used fraction sizes of 7 Gy and 8 Gy. The results also showed no significant differences in the maximum ((r) 0.9029, p < 0.0001 [S]; t test p = 0.2576 [NS], 95% CI − 0.21 to 0.06) and mean ((r) 0.9766, p < 0.0001 [S]; t test p = 0.2786 [NS], 95% CI − 0.93 to 0.03) doses taken from treatment planning system assigned dose points coinciding with the imaged probes of the in vivo dosimeter.

Conclusion

Overall, this study was able to provide additional evidence that in vivo dosimetry can be validly used in the clinical setting to estimate the dose to the rectum during Co-60 HDR brachytherapy. Use of this technique allows for an additional quality assurance method that can contribute to reductions of errors in dose delivery.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

Weitere Produktempfehlungen anzeigen
Literatur
Über diesen Artikel
  1. Sie können e.Med Radiologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise